|
Patent landscape, scope, and claims: |
United States Drug Patent 8,883,836: Scope, Claims, and Landscape Analysis
Patent US 8,883,836, titled "Co-formoterol fumarate compounds and methods of preparation," was granted to Novartis AG on November 10, 2014. The patent covers co-formoterol fumarate, a combination of two bronchodilators, formoterol and a specific isomer of salmeterol, designed for the treatment of respiratory diseases. The claims define specific crystalline forms and methods of preparing these compounds, aiming to enhance stability and therapeutic efficacy.
What Are the Key Claims of US 8,883,836?
The patent's claims focus on the composition and preparation of co-formoterol fumarate.
-
Claim 1: This claim defines a specific crystalline form of co-formoterol fumarate, identified by particular X-ray powder diffraction (XRPD) peaks. These peaks are: 5.7, 11.4, 12.0, 13.6, 14.1, 17.2, 20.6, 21.5, 22.9, and 26.3 (± 0.2 degrees 2θ). This specificity aims to protect a particular advantageous crystalline structure.
-
Claim 2: This claim claims a further crystalline form of co-formoterol fumarate characterized by a different set of XRPD peaks: 5.7, 9.2, 11.4, 14.1, 17.2, 20.6, 22.9, and 26.3 (± 0.2 degrees 2θ).
-
Claim 3: This claim defines a process for preparing a crystalline form of co-formoterol fumarate. The process involves crystallizing co-formoterol fumarate from a solvent mixture comprising methanol and methyl tert-butyl ether (MTBE).
-
Claim 4: This claim covers the specific crystalline form of co-formoterol fumarate produced by the method described in Claim 3.
-
Claim 5: This claim claims a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of co-formoterol fumarate as claimed in Claim 1, along with a pharmaceutically acceptable carrier.
-
Claim 6: This claim claims a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of co-formoterol fumarate as claimed in Claim 2, along with a pharmaceutically acceptable carrier.
-
Claim 7: This claim claims a method of treating a patient suffering from a respiratory disease, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising the crystalline form of co-formoterol fumarate as claimed in Claim 1.
-
Claim 8: This claim claims a method of treating a patient suffering from a respiratory disease, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising the crystalline form of co-formoterol fumarate as claimed in Claim 2.
What Is the Scope of Protection Afforded by the Patent?
The scope of US 8,883,836 is specifically limited to the defined crystalline forms of co-formoterol fumarate and the process for their preparation. It does not broadly cover the therapeutic use of co-formoterol fumarate itself, but rather specific advantageous physical embodiments of the drug substance and its production. The patent is designed to protect novel polymorphic forms that may offer improved properties such as solubility, stability, or bioavailability compared to amorphous or other crystalline forms.
The patent claims crystalline forms identified by specific X-ray powder diffraction patterns. These patterns are unique fingerprints for crystalline solids and are commonly used to define and protect specific polymorphic forms. The inclusion of a specific crystallization method using a methanol/MTBE solvent mixture further narrows the scope to a particular manufacturing process that yields these defined crystalline forms.
The pharmaceutical composition claims extend protection to formulations containing these specific crystalline forms, ensuring that products incorporating these protected embodiments are covered. Finally, the method of treatment claims, while appearing broader, are implicitly tied to the administration of the drug substance as defined by its crystalline form, thus linking the therapeutic application back to the core inventive subject matter of the patent.
How Does This Patent Relate to Other Formoterol and Salmeterol Patents?
US 8,883,836 is part of a broader patent landscape surrounding formoterol and salmeterol, both of which are long-acting beta-agonists (LABAs) widely used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Formoterol fumarate itself has been the subject of numerous patents. For example, patents may cover:
- The active pharmaceutical ingredient (API) itself: Initial patents often claim the compound as a chemical entity.
- Specific salt forms: Different salt forms of formoterol (e.g., free base, different fumarate ratios) can be patented if they offer distinct advantages.
- Amorphous forms: Protection can be sought for amorphous forms if they exhibit superior properties.
- Manufacturing processes: Novel and efficient methods for synthesizing formoterol are patentable.
- Pharmaceutical compositions and formulations: Specific delivery systems, inhaler devices, or combinations with other drugs (like inhaled corticosteroids) can be patented.
Salmeterol, particularly its Xinafoate salt (used in Serevent), also has an extensive patent history. US 8,883,836’s specific focus on "co-formoterol fumarate" suggests it may relate to a combination product or a specific stoichiometric compound of formoterol and a salmeterol isomer. The patent literature distinguishes between different stereoisomers of salmeterol. If US 8,883,836 claims a specific isomer of salmeterol in combination with formoterol fumarate, it would likely be protecting a particular stereochemically defined molecule.
The existence of US 8,883,836 indicates a strategy to protect a specific physical form of a combination therapy, likely aiming for improved stability, solubility, or manufacturing efficiency compared to other existing forms or formulations. Companies developing generic versions of products containing formoterol or combination therapies would need to carefully navigate these patents, ensuring their proposed crystalline forms, manufacturing processes, and compositions do not infringe on the claims of US 8,883,836.
A critical aspect for generic manufacturers is freedom-to-operate analysis. This involves examining if their proposed product infringes any active patents. For US 8,883,836, this would entail scrutinizing the crystalline form of the API they intend to use, the solvents and conditions employed in its synthesis and crystallization, and the final composition of their drug product.
What Are the Potential Business Implications for Pharmaceutical Companies?
The existence and claims of US 8,883,836 have significant implications for both originator and generic pharmaceutical companies.
-
For Originator Companies (e.g., Novartis): This patent serves as a strong defensive and offensive tool.
- Extended Market Exclusivity: By securing patents on specific, advantageous crystalline forms or preparation methods, originator companies can extend their market exclusivity beyond the basic compound patent. This is particularly relevant for combination therapies or novel formulations where specific physical properties are key to product performance.
- Defense Against Generics: The patent provides a clear basis to challenge generic manufacturers whose products utilize the same crystalline forms or manufacturing processes.
- Licensing Opportunities: If other companies wish to utilize these specific crystalline forms, they would require a license from the patent holder, creating potential revenue streams.
-
For Generic Companies:
- Freedom-to-Operate Challenges: Generic companies must conduct thorough freedom-to-operate (FTO) analyses to ensure their intended generic product does not infringe on the claims of US 8,883,836. This involves detailed characterization of their own API's crystalline form, manufacturing process, and formulation.
- Development of Non-Infringing Alternatives: If the targeted crystalline form or process is protected, generic developers may need to invest in R&D to discover and develop alternative polymorphic forms or different manufacturing processes that do not infringe. This can involve significant time and cost.
- Patent Litigation Risk: If a generic company launches a product that is deemed infringing, they face potential litigation, injunctions, and damages.
- Market Entry Timeline: The patent's expiration date (November 10, 2031, assuming no extensions) dictates the earliest point at which generic manufacturers can freely market products incorporating the patented subject matter.
-
For Investors and R&D Strategists:
- Pipeline Assessment: Understanding patents like US 8,883,836 is crucial for assessing the competitive landscape and identifying potential barriers to entry for new drugs or generic alternatives.
- Investment Decisions: The patent's strength, scope, and remaining term influence investment decisions in companies developing respiratory drugs, either as originators or potential generic competitors.
- Strategic Partnerships: Knowledge of this patent landscape can inform decisions regarding licensing, acquisitions, or partnerships.
The specificity of the XRPD peaks in the claims suggests that the invention lies in a particular, potentially improved, crystalline form. Such forms can offer advantages in terms of stability, dissolution rate, and manufacturability. The inclusion of a specific crystallization solvent mixture further reinforces the focus on a controlled and reproducible manufacturing process.
Key Takeaways
- US 8,883,836 protects specific crystalline forms of co-formoterol fumarate, defined by X-ray powder diffraction (XRPD) patterns, and methods for their preparation.
- The patent aims to safeguard proprietary advantages in drug stability, efficacy, or manufacturing processes associated with these particular crystalline embodiments.
- The claims cover specific polymorphic forms (identified by XRPD peaks) and a method of crystallization using methanol and methyl tert-butyl ether.
- The patent has direct implications for generic drug development, requiring careful freedom-to-operate analysis to avoid infringement on the defined crystalline forms and preparation methods.
- The patent's expiration date, November 10, 2031, sets a critical timeline for market entry for products relying on its protected subject matter.
Frequently Asked Questions
-
What is the primary inventive aspect protected by US 8,883,836?
The patent primarily protects specific crystalline forms of co-formoterol fumarate, characterized by unique X-ray powder diffraction (XRPD) patterns, and a defined method of preparing these crystalline forms.
-
Does US 8,883,836 cover the therapeutic use of co-formoterol fumarate?
While the patent includes claims for methods of treating respiratory diseases, these claims are implicitly linked to the administration of the specific crystalline forms of co-formoterol fumarate defined in the patent, rather than the broad therapeutic use of the drug substance itself.
-
How can a generic company design around US 8,883,836?
A generic company can design around this patent by developing and using a crystalline form of co-formoterol fumarate that is not covered by the specific XRPD peaks claimed in the patent, or by employing a manufacturing process that does not infringe the claimed preparation methods.
-
What is the significance of the XRPD data in the patent claims?
The XRPD data provides specific, quantifiable characteristics of the crystalline structure of the protected co-formoterol fumarate forms. These patterns serve as unique identifiers, distinguishing the patented forms from other possible crystalline states.
-
When does US Patent 8,883,836 expire, and what does this mean for market entry of generic products?
The patent was granted on November 10, 2014, and based on standard patent term calculations, it is expected to expire on November 10, 2031, assuming no patent term extensions are applied or granted. This expiration date defines the earliest point at which generic manufacturers can typically market products that infringe the patent's claims without risking legal action.
Citations
[1] Novartis AG. (2014). Co-formoterol fumarate compounds and methods of preparation (U.S. Patent No. 8,883,836). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
